Carbonic anhydrase inhibition in the management of symptomatic peptic ulcers

The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers. In memoriam Ioan Puşcaş (1932–2015)

“…Work done in 1956 at the Chemical Defence Experimental Establishment, Liverpool, showed that acetazolamide in usual doses did not abolish HCl secretion 27 , but, in 1956, Rodolfo Cheli (1928-1997) reported some inhibitory effects in normal subjects and chronic gastritis patients 28 . In 1960, acetazolamide was introduced to the therapy of peptic ulcers in a military hospital from Illinois, USA 29 . Acetazolamide was given in a dose of 250 mg q.i.d.…”